223 related articles for article (PubMed ID: 38372871)
61. Treatment patterns and long-term persistence with osteoporosis therapies in women with Medicare fee-for-service (FFS) coverage.
Singer AJ; Liu J; Yan H; Stad RK; Gandra SR; Yehoshua A
Osteoporos Int; 2021 Dec; 32(12):2473-2484. PubMed ID: 34095966
[TBL] [Abstract][Full Text] [Related]
62. Association between pharmacotherapy and secondary hip fracture in a real-world setting: a nationwide database study.
Nakatoh S; Fujimori K; Ishii S; Tamaki J; Okimoto N; Ogawa S; Iki M
J Bone Miner Metab; 2023 Mar; 41(2):248-257. PubMed ID: 36853423
[TBL] [Abstract][Full Text] [Related]
63. Bisphosphonate and denosumab initiation in older adults in Ontario, Canada: a population-based cohort study.
Clemens KK; Jeyakumar N; Ouédraogo AM; Thain J; Khan T
Arch Osteoporos; 2020 Aug; 15(1):133. PubMed ID: 32816151
[TBL] [Abstract][Full Text] [Related]
64. Therapeutic Options for the Management of Aromatase Inhibitor- Associated Bone Loss.
Gaudio A; Xourafa A; Rapisarda R; Castellino P
Endocr Metab Immune Disord Drug Targets; 2022; 22(3):259-273. PubMed ID: 34370654
[TBL] [Abstract][Full Text] [Related]
65. Incidence and Risk of Venous Thromboembolism in Bisphosphonates and Selective Estrogen Receptor Modulators Treatment in Korea.
Park SY; Kim SH; Kim TY; Lee YK; Ha YC; Jang S; Ahn SH; Kim HY
J Korean Med Sci; 2021 Jul; 36(27):e186. PubMed ID: 34254473
[TBL] [Abstract][Full Text] [Related]
66. Current options for the management of postmenopausal osteoporosis.
Lecart MP; Reginster JY
Expert Opin Pharmacother; 2011 Nov; 12(16):2533-52. PubMed ID: 21916810
[TBL] [Abstract][Full Text] [Related]
67. New anti-resorptives and antibody mediated anti-resorptive therapy.
Farrier AJ; Sanchez Franco LC; Shoaib A; Gulati V; Johnson N; Uzoigwe CE; Choudhury MZ
Bone Joint J; 2016 Feb; 98-B(2):160-5. PubMed ID: 26850419
[TBL] [Abstract][Full Text] [Related]
68. Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medications.
Body JJ; Bergmann P; Boonen S; Devogelaer JP; Gielen E; Goemaere S; Kaufman JM; Rozenberg S; Reginster JY
Osteoporos Int; 2012 Feb; 23 Suppl 1(Suppl 1):S1-23. PubMed ID: 22311111
[TBL] [Abstract][Full Text] [Related]
69. Changes in serum vitamin D and PTH values using denosumab with or without bisphosphonate pre-treatment in osteoporotic patients: a short-term study.
Nakamura Y; Kamimura M; Ikegami S; Mukaiyama K; Uchiyama S; Taguchi A; Kato H
BMC Endocr Disord; 2015 Dec; 15():81. PubMed ID: 26666998
[TBL] [Abstract][Full Text] [Related]
70. An overview on the treatment of postmenopausal osteoporosis.
Maeda SS; Lazaretti-Castro M
Arq Bras Endocrinol Metabol; 2014 Mar; 58(2):162-71. PubMed ID: 24830593
[TBL] [Abstract][Full Text] [Related]
71. Preventing Osteoporosis in Men Taking Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis.
Joseph JS; Lam V; Patel MI
Eur Urol Oncol; 2019 Sep; 2(5):551-561. PubMed ID: 31411986
[TBL] [Abstract][Full Text] [Related]
72. [Current topics in drug therapy aiming at bone resorption].
Yasui T; Tanaka S
Clin Calcium; 2006 Sep; 16(9):1475-79. PubMed ID: 16951471
[TBL] [Abstract][Full Text] [Related]
73. Pharmacological management of osteogenesis.
Nardone V; D'Asta F; Brandi ML
Clinics (Sao Paulo); 2014 Jun; 69(6):438-46. PubMed ID: 24964310
[TBL] [Abstract][Full Text] [Related]
74. Differential Effects of Teriparatide and Denosumab on Intact PTH and Bone Formation Indices: AVA Osteoporosis Study.
Dempster DW; Zhou H; Recker RR; Brown JP; Recknor CP; Lewiecki EM; Miller PD; Rao SD; Kendler DL; Lindsay R; Krege JH; Alam J; Taylor KA; Janos B; Ruff VA
J Clin Endocrinol Metab; 2016 Apr; 101(4):1353-63. PubMed ID: 26859106
[TBL] [Abstract][Full Text] [Related]
75. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.
Davis S; Simpson E; Hamilton J; James MM; Rawdin A; Wong R; Goka E; Gittoes N; Selby P
Health Technol Assess; 2020 Jun; 24(29):1-314. PubMed ID: 32588816
[TBL] [Abstract][Full Text] [Related]
76. Drug holidays in women treated for postmenopausal osteoporosis.
McClung MR
Menopause; 2018 Oct; 25(10):1152-1154. PubMed ID: 30044265
[TBL] [Abstract][Full Text] [Related]
77. Update on denosumab in postmenopausal osteoporosis--recent clinical data.
Muschitz C; Fahrleitner-Pammer A; Huber J; Preisinger E; Kudlacek S; Resch H
Wien Med Wochenschr; 2012 Sep; 162(17-18):374-9. PubMed ID: 22688622
[TBL] [Abstract][Full Text] [Related]
78. New approaches to the treatment of osteoporosis.
Silva BC; Bilezikian JP
Annu Rev Med; 2011; 62():307-22. PubMed ID: 21054170
[TBL] [Abstract][Full Text] [Related]
79. Efficacy and safety of bazedoxifene, a novel selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis.
Palacios S
Curr Med Res Opin; 2010 Jul; 26(7):1553-63. PubMed ID: 20429824
[TBL] [Abstract][Full Text] [Related]
80. [Absolute risk for fracture and WHO guideline. Selection of drugs for the prevention of fractures in postmenopausal women].
Gorai I;
Clin Calcium; 2007 Jul; 17(7):1090-6. PubMed ID: 17607077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
